{"nct_id":"NCT00099437","title":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2005-02-13","start_date_type":"ACTUAL","primary_completion_date":"2009-02-27","primary_completion_date_type":"ACTUAL","completion_date":"2025-12-31","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}